Moderna
stock shot up after
Merck
said it is exercising an option to work on a personalized cancer vaccine with the Covid-19 vaccine maker.
Merck (ticker: MRK) will pay
Moderna
(MRNA) $250 million for the joint development and future commercialization of the vaccine, which is currently in Phase 2 clinical trials. The two companies had announced a “strategic collaboration” in June 2016.
This website, OkBroadcast.com, gathers all information from publicly accessible sources without making any modifications to the content or source. The original source for each news item is clearly indicated. Our channel provides news, information, and entertainment without any bias, presenting the latest breaking news and videos from the entertainment industry. We obtain our information from RSS feeds and other available sources, and we also create and commission original content in print and video formats, including our own YouTube channel, "VIAYT." We hope you enjoy the diverse range of topics and subjects presented in a constantly evolving world..
Contact us: info@oamericans.com
© OkBroadcast.com, The News, Information % Entertainment Bureau.